Examination of Several Physiological Factors in Females Suffering from Polycystic Ovarian Syndrome (PCOS) in Thi-Qar Governorate
Keywords:
PCOS, FSH, LH, Progesterone and ProlactinAbstract
Polycystic ovarian syndrome (PCOS) is typical disease characterized through irregularmenstruation as well as the biochemical or clinical signs of an overabundance of testosterone . A
person may experience PCOS symptoms at any age. These include early puberty in infancy, hirsutism
and irregular menstruation in adolescence, infertility and glucose intolerance in middle age and later
in life (heart disease and diabetes mellitus). Although a pelvic ultrasound examination is helpful,
polycystic ovaries are a typical condition in females with PCOS, so ultrasound evidence is required
regarding the diagnosis. It is advisable to test for hyperlipidemia and glucose intolerance, particularly
in obese women, as PCOS is frequently associated with diabetes mellitus. The addition of insulinsensitizing medications, such as metformin, may be helpful in situations like anovulatory infertility.
Lifestyle modifications as advised for diabetes are essential for treatment. While clomiphene citrate
with or without metformin, ovarian drilling, gonadotrophin-induced ovulation induction, and diet and
exercise can all help most women manage their infertility, in vitro fertilization should be avoided. .
The DhiQar governorate served as the study's site. It was collected from Bint Al-Huda Maternity
Hospital comprising 100 blood samples drawn from 30 Healthy lady, and 70 blood samples drawn
from women who had pco and were between the ages of 18 and 42 The hormonal analysis for FSH,
LH , Progesterone and Prolactin by using auto analyzer device maglumi . A device was also used
packed cell volume haematocrite to measure Blood ratio.
References
Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the
polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol
Metab 2001; 86: 1626-1632 ..
Badawy, A., & Elnashar, A. (2011). Treatment options for polycystic ovary syndrome. International
journal of women's health, 3, 25
Codner, E., ... & Rudaz, C. G. (2017). An international consortium update .:
Crespo, R. P., Bachega, T. A., Mendonça, B. B., & Gomes, L. G. (2018 An update of genetic basis of
PCOS pathogenesis. Archives of Endocrinology and Metabolism, 62(3), 352-361.
Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of
obesity, in polycystic ovary syndrome. Diabetes 1989; 38 1165 -1174
Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin
Reprod Endocrinol 1994; 12: 15-20
dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002:B7: 5702-5705
Emekci Ozay, O., Ozay, A. C., Acar, B., Cagliyan, E., Seçil, M., & Küme, T. (2016). Role of
kisspeptin in polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 32(9), 7187-22 ..
Farquhar C, Vandekerckhove P, Lilford R. Laparoscopic “drilling” by diathermy or laser for
ovulation induction in anovulatory polycystic ovary syndrome (Cochrane Review). The Cochrane
Library, Issue 2, 2003. Oxford: Update Software..
Farquhar CM, Birdsall M, Manning P, et al. The prevalence of polycystic ovaries on ultrasound
scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994; 34: 67-72.
Fassnacht, M., Schlenz, N., Schneider, S. B., Wudy, S. A., Allolio, BArlt, W. (2003). Beyond
adrenal and ovarian androgen generation: increased peripheral 5α-reductase activity in women with
polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 88(6), 2760-2766.
Group. (2004). Revised 2003 consensus on diagnostic criteria and long‐term
Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrialcarcinoma. Lancet
; 361: 1810-1812.
Ibanez L, Potau N, Ferrer A, et al. Anovulation in eumenorrheic, nonobese adolescent girls born
small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and
reduces abdominal fat excess .,
Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazonerosiglitazone,
pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;
(3): CD003053.
Pasquali, R., Gambineri, A., & Pagotto, U. (2006). The impact of obesity on reproduction in women
with polycystic ovary syndrome. BJOG: An International Journal of Obstetrics & Gynaecology,
(10), 1148-1159..
Norman RJ, Kidson WJ, Cuneo RC, et al. Metformin and intervention in polycystic ovary syndrome.
Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric
Endocrine Group. Med J Aust 2001; 174: 580-583.
Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to
impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian
syndrome. Hum Reprod 2001; 16: 1995-1998.
Norman RJ. Hyperandrogenaemia and the ovary. Mol Cell Endocrinol 2002; 191:113-119
adolescence. Hormone research in paediatrics, 88, 371-395.
Quinn, M., Shinkai, K., Pasch, L., Kuzmich, L., Cedars, M Huddleston, H. (2014). Prevalence of
androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated
clinical and biochemical features. Fertility and sterility, 101(4), 1129-1134.
Recabarren, S. E., Smith, R., Rios, R., Maliqueo, M., Echiburu, B Codner, E., ... & Sir-Petermann,
T. (2008). Metabolic profile in sons of women with polycystic ovary syndrome. The Journal of
Clinical Endocrinology & Metabolism, 93(5), 1820-1826.
Rotteram ESH E/ S M‐Sponsore COS Consensus Workshop reproduction, 19(1), 41-47.
Sirmans, S. M., & pate, K. A. (2014). Epidemiology, diagnosis, and management of polycystic
ovary syndrome. Clinical epidemiology, 6, 1..
Tarrade A, Schoonjans K, Pavan L, etal. PPARgamma/RXRalpha heterodimers control human
trophoblast invasion. J Clin Endocrinol Metab 2001; 86: 5017-5024.
Valkenburg, O., Steegers-Theunissen, R. P., Smedts, H. P., Dallinga-Thie G. M., Fauser, B. C.,
Westerveld, E. H., & Laven, J. S. (2008). A more atherogenic serum lipoprotein profile is present in
women with polycystic ovary syndrome: a case-control study. The Journal Of Clinical Endocrinology
Metabolism, 93(2), 470-476..
Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary
syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52:
Downloads
Published
Issue
Section
License
Copyright (c) 2024 University of Thi-Qar Journal Of Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
